Gastric cancer abstracts

292 abstracts

Abstract Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients Congress:ESMO 2024, Search all connections
Abstract SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer Congress:ESMO 2024, Search all connections
Abstract Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer Congress:ESMO 2024, Search all connections
Abstract Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy Congress:ESMO 2024, Search all connections
Abstract Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group â€“ The IKF-057/ PRESTO trial Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study Congress:ESMO 2024, Search all connections
Abstract Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy Congress:ESMO 2024, Search all connections
Abstract Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC) Congress:ESMO 2024, Search all connections
Abstract Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer Congress:ESMO 2024, Search all connections
Abstract Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer Congress:ESMO 2024, Search all connections
Abstract Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy Congress:ESMO 2024, Search all connections
Abstract Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer Congress:ESMO 2024, Search all connections
Abstract Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a) Congress:ESMO 2024, Search all connections
Abstract Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysis Congress:ESMO 2024, Search all connections
Abstract First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2â€“) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2 Congress:ESMO 2024, Search all connections
Abstract Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer Congress:ESMO 2024, Search all connections
Abstract Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial Congress:ESMO 2024, Search all connections
Abstract Intestinal microbiota as a biological marker for pre-neoplastic lesion in gastric cancer in Amazonas, Brazil Congress:ESMO 2024, Search all connections
Abstract AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysis Congress:ESMO 2024, Search all connections
Abstract Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial) Congress:ESMO 2024, Search all connections
Abstract Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer Congress:ESMO 2024, Search all connections
Abstract Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer Congress:ESMO 2024, Search all connections
Abstract The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Abstract Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. Congress:ASCO 2019, Search all connections
Abstract Treatment modalities and oncological outcomes in a cohort of patients with advanced gastric cancer in Mexico. Congress:ASCO 2019, Search all connections
Abstract Disassociation of ARID1A with genomic ancestry and prognostic impact in an admixed cohort of Brazilian patients with gastric cancer (GC). Congress:ASCO 2019, Search all connections
Abstract Survival of gastric cancer (GC) patients is not determined by the predominant genomic ancestry (PGA): Results from an ethnically admixed Brazilian cohort of GC patients. Congress:ASCO 2019, Search all connections
Abstract Clinical significance of peritoneal molecular markers in patients with locally advanced gastric cancer (LAGC) without macroscopic peritoneal implants treated with perioperative chemotherapy (ChT). Congress:ASCO 2019, Search all connections
Abstract Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC). Congress:ASCO 2019, Search all connections
Abstract Effect of p-PAQR3Thr32 on PD-L1 expression and immune evasion in gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Is it possible to effectively treat second-line gastric cancer, given the prognosis factors? Congress:ASCO 2019, Search all connections
Abstract Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers. Congress:ASCO 2019, Search all connections
Abstract Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience. Congress:ASCO 2019, Search all connections
Abstract Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers. Congress:ASCO 2019, Search all connections
Abstract Factors predicting poor survival in early gastric cancer: A SEER analysis. Congress:ASCO 2019, Search all connections
Abstract Final results of early non-invasive gastric cancer detection study using the serum pepsinogen test method in Croatian patients. Congress:ASCO 2019, Search all connections
Abstract Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection. Congress:ASCO 2019, Search all connections
Abstract Survival analysis and clinical characteristics of forty-eight patients with alpha-fetoprotein-positive gastric cancer treated by integrated Chinese and western medicine. Congress:ASCO 2019, Search all connections
Abstract Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: A randomized controlled study. Congress:ASCO 2019, Search all connections
Abstract Molecular mechanism of chemoresistance and restoration in human gastric cancer cells. Congress:ASCO 2019, Search all connections
Abstract Prevalence of gastric cancer and premalignant changes in a Michigan cohort, 2013-2017. Congress:ASCO 2019, Search all connections
Abstract Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDl-1 expression in Turkish patients with gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Expression of CD44 and CD133 in tumor сells of metastatic and non-metastatic gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Can hormone receptors prevent metastatic spread of gastric cancer? Congress:ASCO 2019, Search all connections
Abstract Predictors of peritoneal metastasis in gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis. Congress:ASCO 2019, Search all connections
Abstract Clinical efficacy and safety in gastric cancer patients treated with apatinib: A retrospective real-world study. Congress:ASCO 2019, Search all connections
Abstract Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study. Congress:ASCO 2019, Search all connections
Abstract The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis. Congress:ASCO 2019, Search all connections
Abstract Impact of adjuvant treatment according to gastric cancer molecular subtypes. Congress:ASCO 2019, Search all connections
Abstract Correlation of CHAF1A with adjuvant chemotherapy outcome and microsatellite instability in gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Prognostic value and clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in resected gastric cancer: A meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of conversion therapy using chemotherapy plus anti-angiogenic therapy in unresectable gastric cancer. Congress:ASCO 2019, Search all connections
Abstract A multicenter, single-armed, prospective phase II study of apatinib combined with chemotherapy neoadjuvant for locally advanced gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Safety and efficacy of neoadjuvant chemotherapy with S-1 and oxaliplatin plus apatinib for locally advanced gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Effect of tivantinib on VEGF signaling pathways and apoptosis of gastric cancer cells with c-MET or VEGFA amplification. Congress:ASCO 2019, Search all connections
Abstract Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence. Congress:ASCO 2019, Search all connections
Abstract Integrin β5 in plasma-derived exosomal protein predicting liver-specific metastasis in advanced gastric cancer patients. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world. Congress:ASCO 2019, Search all connections
Abstract Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). Congress:ASCO 2019, Search all connections
Abstract Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study. Congress:ASCO 2019, Search all connections
Abstract Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases. Congress:ASCO 2019, Search all connections
Abstract Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling. Congress:ASCO 2019, Search all connections
Abstract Prospective validation of a serum miRNA panel for early detection of gastric cancer. Congress:ASCO 2019, Search all connections
Abstract The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy. Congress:ASCO 2019, Search all connections
Abstract Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy. Congress:ASCO 2019, Search all connections
Abstract Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Congress:ASCO 2019, Search all connections
Abstract Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience. Congress:ASCO 2019, Search all connections
Abstract Homologous recombination deficiency as prognostic marker in metastatic gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients. Congress:ASCO 2019, Search all connections
Abstract POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial. Congress:ASCO 2019, Search all connections
Abstract A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer. Congress:ASCO 2019, Search all connections
Abstract Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE). Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations. Congress:ASCO 2019, Search all connections
Abstract Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody. Congress:ASCO 2019, Search all connections
Abstract Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study. Congress:ASCO 2019, Search all connections
Abstract A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer patients. Congress:ASCO 2019, Search all connections
Abstract Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19). Congress:ASCO 2019, Search all connections
Abstract Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912). Congress:ASCO 2019, Search all connections
Abstract ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). Congress:ASCO 2019, Search all connections
Abstract Prolonged overall survival observed in patients with locally advanced gastric cancer receiving prophylactic simplified heated intraperitoneal chemotherapy after D2 surgery. Congress:ASCO 2021, Search all connections
Abstract Pre-treatment status of inflammation-based biomarkers in the patients with advanced gastric cancer who will be treated with nivolumab. Congress:ASCO 2021, Search all connections
Abstract LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study. Congress:ASCO 2021, Search all connections
Abstract Matched therapies for advanced gastric cancer based on genotype: A real-world study in China. Congress:ASCO 2021, Search all connections
Abstract Phase II study of combining immunotherapy and pulsed low dose rate radiotherapy for abdominal metastasis of gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Cellworks Omics Biology Model (CBM) to predict therapy response and identify novel biomarkers for 5FU-based combination therapy in gastric cancer patients. Congress:ASCO 2021, Search all connections
Abstract HER2-low and gastric cancer: A prognostic biomarker? Congress:ASCO 2021, Search all connections
Abstract A noninvasive gastric cancer Her2 test using surrogate methylation markers. Congress:ASCO 2021, Search all connections
Abstract Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Cost-effectiveness analysis of gastric cancer management using perioperative chemotherapy versus adjuvant chemoradiation therapy. Congress:ASCO 2021, Search all connections
Abstract Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and hemoglobin (Hb) predict immunotherapy outcomes in patients with advanced or metastatic gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Prognostic value of subclassification of pT2 stage in patients with gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Optimizing the program of sequential chemotherapy for advanced gastric cancer based on gene-level CNVs called from ctDNA. Congress:ASCO 2021, Search all connections
Abstract Profiling genomic characteristics related to immunotherapy for gastric cancer with amplified MET. Congress:ASCO 2021, Search all connections
Abstract Assessment of the prognostic significance of clinical and morphological factors on the survival of patients with locally advanced gastric cancer after radical surgical treatment: The experience of the Russian Center. Congress:ASCO 2021, Search all connections
Abstract TRG as indicator of efficacy of FLOT versus FOLFOX in perioperative chemotherapy for resectable gastric cancer patients (single institution experience). Congress:ASCO 2021, Search all connections
Abstract CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC). Congress:ASCO 2021, Search all connections
Abstract Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study. Congress:ASCO 2021, Search all connections
Abstract Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study. Congress:ASCO 2021, Search all connections
Abstract The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An additional analysis of JCOG1013. Congress:ASCO 2021, Search all connections
Abstract A prospective, randomized, controlled, multicenter study of apatinib combined with S-1 plus docetaxel as adjuvant therapy for locally advanced gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Lymph node metastases of gastric cancer and blood cell circuit. Congress:ASCO 2021, Search all connections
Abstract Changes in neutrophil /lymphocyte ratio and platelet count after chemotherapy correlate with cheomtherapy response and predicition of prognosis in patients with advanced gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Detection of genes related to peritoneal metastasis of primary gastric cancer based on large-panel Next Generation Sequencing. Congress:ASCO 2021, Search all connections
Abstract Apatinib plus paclitaxel versus placebo plus paclitaxel as second-line therapy in patients with gastric cancer with peritoneal carcinomatosis: A double-blind, randomized phase II trial. Congress:ASCO 2021, Search all connections
Abstract Clinical features, treatments and survival of HER2 positive gastric cancer with elevated alpha-fetoprotein: An analysis of 16 cases. Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety of intermittent versus continuous dosing schedule of apatinib combined with docetaxel as second-line treatment for advanced gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Survival impact among occidental patients with metastatic gastric cancer (mGC) treated with ramucirumab as second line treatment (2L): Local experience of a teaching hospital in Chile. Congress:ASCO 2021, Search all connections
Abstract Camrelizumab combined with SOX regimen in the first-line treatment of unresectable advanced or recurrent gastric cancer: A single-arm, prospective, open clinical study. Congress:ASCO 2021, Search all connections
Abstract Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability. Congress:ASCO 2021, Search all connections
Abstract PD-1 antibody (Camrelizumab) for metastatic EBV positive gastric cancer: A prospective single-arm, open-label, phase 2 trial. Congress:ASCO 2021, Search all connections
Abstract Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial. Congress:ASCO 2021, Search all connections
Abstract Activity of daily living of elderly patients with gastric cancer after surgery. Congress:ASCO 2021, Search all connections
Abstract EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study. Congress:ASCO 2021, Search all connections
Abstract Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903). Congress:ASCO 2021, Search all connections
Abstract Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress. Congress:ASCO 2021, Search all connections
Abstract Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET. Congress:ASCO 2021, Search all connections
Abstract A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Congress:ASCO 2021, Search all connections
Abstract Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Congress:ASCO 2021, Search all connections
Abstract Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Long-term quality of life and nutritional results after laparoscopic sentinel node navigation surgery versus laparoscopic standard gastrectomy for early gastric cancer: Secondary outcomes of a multicenter, randomized phase 3 trial (SENORITA). Congress:ASCO 2021, Search all connections
Abstract Risk factors of metachronous peritoneal carcinomatosis after potentially curative gastric cancer resection in the CRITICS trial. Congress:ASCO 2021, Search all connections
Abstract Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004. Congress:ASCO 2021, Search all connections
Abstract Risk factors for recurrence in each pattern after curative gastrectomy for pStage II/III gastric cancer: An exploratory analysis of a randomized controlled trial (JCOG1001). Congress:ASCO 2021, Search all connections
Abstract Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08). Congress:ASCO 2021, Search all connections
Abstract A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701). Congress:ASCO 2021, Search all connections
Abstract Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥3 in oesophago-gastric cancer (OGC). Congress:ASCO 2021, Search all connections
Abstract DNA and RNA sequencing analysis revealed alterations of ANK3, PKHD1 and olfactory transduction as potential biomarker of three-year survival in gastric cancer. Congress:ASCO 2021, Search all connections
Abstract LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. Congress:ASCO 2021, Search all connections
Abstract Frequency of homologous recombination-related (HRR) genes mutations in gastric cancer. Congress:ASCO 2021, Search all connections
Abstract Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study. Congress:ASCO 2021, Search all connections
Abstract Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort. Congress:ASCO 2021, Search all connections
Abstract The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial. Congress:ASCO 2021, Search all connections
Abstract PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy. Congress:ASCO 2021, Search all connections
Abstract Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial. Congress:ASCO 2021, Search all connections
Abstract First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. Congress:ASCO 2021, Search all connections
Abstract Application of value framework to phase III trials of immune checkpoint inhibitors in esophageal and gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study. Congress:ASCO 2022, Search all connections
Abstract Does hyponatremia predict worse outcomes in gastric cancer?: A nationwide study. Congress:ASCO 2022, Search all connections
Abstract Demographic differences in the treatment of gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial. Congress:ASCO 2022, Search all connections
Abstract Molecular profile of exosomal miRNA differential expression in ascites of untreated advanced gastric cancer patients with peritoneal metastases. Congress:ASCO 2022, Search all connections
Abstract Genomic characterization of Chinese locally advanced or metastatic gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Genomic alteration in chromatin remodeling genes as a potential predictive biomarker for immunotherapy in gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Differences in outcomes between premenopausal women and men with gastric cancer in the United States. Congress:ASCO 2022, Search all connections
Abstract Relationship between tumor infiltrating lymphocytes and clinicopathological features in Peruvian gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial. Congress:ASCO 2022, Search all connections
Abstract Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study. Congress:ASCO 2022, Search all connections
Abstract FLOT neoadjuvant therapy turns the expression patterns of cancer cells similar to those of non-cancer cells in gastric cancer patients. Congress:ASCO 2022, Search all connections
Abstract Comparison of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy in the treatment of Borrmann type IV gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systematic therapy of gastric cancer. Congress:ASCO 2022, Search all connections
Abstract A systematic review and meta-analysis to evaluate the efficacy and safety of nivolumab for advanced esophageal, gastroesophageal, and gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Responses to the MET inhibitor tepotinib in gastric cancers with MET amplification or both high PD-L1 expression and an MET exon 14 skipping mutation. Congress:ASCO 2022, Search all connections
Abstract Detection of targetable fusion alterations in gastric cancer in the Chinese population. Congress:ASCO 2022, Search all connections
Abstract Development of combination strategies for focal adhesion kinase inhibition in diffuse gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Elevated serum alpha-fetoprotein is a significant prognostic factor for gastric cancer patients: Results based on a large-scale retrospective study. Congress:ASCO 2022, Search all connections
Abstract Effect of deep neuromuscular block on surgical pleth index-guided remifentanil administration in the elderly undergoing laparoscopic gastrectomy for gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Comparison of surgical resection combined with chemotherapy and palliative chemotherapy for synchronous hepatic metastases from gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Cambrelizumab plus chemotherapy as conversion therapy for unresectable metastatic gastric cancer: A single-arm, multicenter, prospective clinical trial. Congress:ASCO 2022, Search all connections
Abstract Assessment of effectiveness of neoadjuvant chemotherapy in patients with resectable gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Intratumoral CD8+ t cell as a potential positive predictor for treatment of chemo-immunotherapy in PD-L1 negative advanced gastric cancer patients. Congress:ASCO 2022, Search all connections
Abstract Prediction of peritoneal cancer index and prognosis in peritoneal metastasis of gastric cancer using NLR-PLR-DDI score. Congress:ASCO 2022, Search all connections
Abstract ScRNA-seq based copy number variations (CNVs) detection identified TPSB2 and TPSAB1 as prognostic biomarkers in Gastric Cancer(GC). Congress:ASCO 2022, Search all connections
Abstract Prognostic and predictive impact of circulating tumor DNA in advanced gastric cancer treated with immune checkpoint blockade. Congress:ASCO 2022, Search all connections
Abstract Different gene mutations among gastric cancer patients with MSS and MSI-H types in China. Congress:ASCO 2022, Search all connections
Abstract Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer. Congress:ASCO 2022, Search all connections
Abstract Sintilimab combined with chemotherapy in conversion therapy of advanced gastric cancer: A retrospective study. Congress:ASCO 2022, Search all connections
Abstract First-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation with infusional fluorouracil and weekly docetaxel: A multicenter, phase II clinical trail. Congress:ASCO 2022, Search all connections
Abstract A real-world assessment of genomic testing and treatment in stage 4 gastric cancer patients. Congress:ASCO 2022, Search all connections
Abstract PD-1 inhibitors combined with apatinib for advanced diffuse gastric cancer: A retrospective study. Congress:ASCO 2022, Search all connections
Abstract Tumor microenvironment (TME) dynamics following capecitabine/oxaliplatin (CapeOx) plus pembrolizumab in patients with advanced gastric cancer. Congress:ASCO 2022, Search all connections
Abstract A next generation site-specific ADC targeting breast and gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Exosome in ascites can be a potential therapeutic target for gastric cancer with malignant ascites. Congress:ASCO 2022, Search all connections
Abstract Anti-PD1, capecitabine, and oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): A proof-of-principle study (AuspiCiOus). Congress:ASCO 2022, Search all connections
Abstract Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Outcomes in patients undergoing curative surgery for gastric cancer by facility type and socioeconomic factors: An analysis of the National Cancer Database (NCDB). Congress:ASCO 2022, Search all connections
Abstract The 27-gene IO score is associated with molecular features and response to immune checkpoint inhibitors (ICI) in patients with gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Clinical efficacy of laparoscopic sentinel node navigation surgery for early gastric cancer: Five-year results of SENORITA trial. Congress:ASCO 2022, Search all connections
Abstract Prognostic role of tumor stroma ratio, tumor-infiltrating lymphocytes, and tumor budding in patients with intestinal-type gastric cancer after radical resection. Congress:ASCO 2022, Search all connections
Abstract A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection. Congress:ASCO 2022, Search all connections
Abstract A biological network approach for mining target genes in EBV-positive gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Circulating tumor DNA and recurrence risk in stage II-III gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Claudin 18 (CLDN18) gene expression and related molecular profile in gastric cancer (GC). Congress:ASCO 2022, Search all connections
Abstract A 107-gene Nanostring assay effectively characterizes complex multiomic gastric cancer molecular classification in a translational patient-derived organoid model. Congress:ASCO 2022, Search all connections
Abstract Characterization of NY-ESO-1 gene expression in gastric cancer (GC). Congress:ASCO 2022, Search all connections
Abstract Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation and replacement of T cell clones in patients with gastric cancer (phase I/II clinical study). Congress:ASCO 2022, Search all connections
Abstract Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer. Congress:ASCO 2022, Search all connections
Abstract Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Congress:ASCO 2022, Search all connections
Abstract The association of B7-H6 expression to the immune microenvironment in gastric cancer. Congress:ASCO 2022, Search all connections
Abstract The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC). Congress:ASCO 2022, Search all connections
Abstract Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. Congress:ASCO 2022, Search all connections
Abstract Point-of-care isoenzyme type M2 pyruvate kinase quick stool test for the detection of gastric cancer in Rwanda: A pilot study. Organization:Dartmouth-Hitchcock ...,University of Rwanda,College of Medicine ...,Drug:ScheBo M2-PK Quick t..., Search all connections
Abstract Early onset gastric cancer: An analysis of epidemiological and environmental risk factors. Organization:Olive-View UCLA Medi...,Sylmar, CA,Department of Surger..., Search all connections
Abstract Development of a plasma biomarker panel for gastric cancer detection based on an autoimmune response signature. Organization:MD Anderson Cancer C...,University of Texas ...,The University of Te...,Congress:ASCO 2023, Search all connections
Abstract Development of a postoperative nomogram to predict disease-specific mortality in gastric cancer: A competing risk analysis using variables the AJCC recommends be collected and registered. Organization:Shizuoka Cancer Cent...,Division of Gastric ...,Department of Quanti...,Congress:ASCO 2023, Search all connections
Abstract Outcomes of patients with oesophageal and gastric cancer in relation to their age and metropolitan residential status: A South Australian audit. Organization:Flinders Medical Cen...,Flinders Medical Cen...,Flinders University,...,Congress:ASCO 2023, Search all connections
Abstract Survival analysis comparing neoadjuvant chemoradiotherapy versus perioperative chemotherapy for locoregional gastric cancer. Organization:Maroone Cancer Cente...,Cleveland Clinic Flo...,Weston, FL,Drug:neoadjuvant chemorad...,perioperative chemot...,Target:perioperative chemot..., Search all connections
Abstract A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection. Organization:Shanghai Jiaotong Un...,Renji Hospital Shang...,Drug:camrelizumab,docetaxel,S-1,Target:docetaxel,S-1,camrelizumab, Search all connections
Abstract Co-mutation-based subtyping of Chinese patients with gastric cancer. Organization:The First Hospital o...,Shanghai OrigiMed Co...,Drug:TP53,ERBB4,LRP1B, Search all connections
Abstract Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study. Clinical trial:HenanCH immunotherap...,Organization:Department of Immuno...,Affiliated Cancer Ho...,Henan Cancer Hospita..., Search all connections
Abstract Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 in patients with gastric cancer after gastrectomy based on the registry data base on the National Health Insurance Service (NHIS) database in Korea. Organization:Kyung Hee University...,Kyung Hee University...,Seoul National Unive...,Drug:S-1,CAPOX, Search all connections
Abstract Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial. Clinical trial:Pro20170000375,Organization:Rutgers Cancer Insti...,Winship Cancer Insti...,Division of Surgical..., Search all connections
Abstract Short-term locally advanced gastric cancer management: A cost-effectiveness analysis. Organization:Rutgers- New Jersey ...,The Ohio State Unive...,Jackson Memorial Hos...,Drug:perioperative chemot...,Upfront Surgery,Preoperative Chemora...,Target:Preoperative Chemora..., Search all connections
Abstract Comparison of multi-omics biomarkers via liquid biopsy in early detection of gastric cancer. Organization:Department of Genera...,Burning Rock Bioengi...,Drug:cfDNA methylation,ctDNA mutation,serum protein marker...,Target:ctDNA mutation,serum protein marker...,cfDNA methylation, Search all connections
Abstract A risk-scoring prognostic model of gastric cancer based on angiogenesis. Organization:The Affiliated Cance...,Congress:ASCO 2023, Search all connections
Abstract Identification of FEN1 as a prognostic marker and novel therapeutic target in gastric cancer harboring TP53 mutations. Organization:Department of Gastro...,Tianjin Medical Univ...,Drug:fen1,Target:FEN1,Congress:ASCO 2023, Search all connections
Abstract The mutational landscape of circulating cell free DNA in patients with gastric cancer. Organization:The First Affiliated...,Department of Oncolo...,The First Affiliated...,Drug:TP53,LRP1B,ARID1A, Search all connections
Abstract Effect of overexpression of ERK1/2 and MDR1 on chemoresistance in advanced gastric cancer patients. Organization:Chittaranjan Nationa...,Chiittaranjan Nation...,Drug:docetaxel,mFOLFOX6,Target:MDR1,ERK1/2,Congress:ASCO 2023, Search all connections
Abstract Clinical analysis of immunotherapy rechallenge in advanced gastric cancer. Organization:Henan Cancer Hospita...,China National Biote...,Zhengzhou Genscience...,Drug:PD-1 monoclonal anti...,Target:PD-1,Congress:ASCO 2023, Search all connections
Abstract Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models. Organization:Columbia University ...,Tonix Pharmaceutical...,Columbia University ...,Drug:TFF2-MSA,PD-1 antibody,mFOLFOX6,Target:CXCR4,PD-1, Search all connections
Abstract Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06). Organization:Soonchunhyang Univer...,Pusan National Unive...,Ulsan University Hos..., Search all connections
Abstract Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study. Organization:The First Affiliated...,Chaohu Hospital of A...,People's Liberation ..., Search all connections
Abstract Assessing the real-world experience of treating gastric cancer in Armenia: A retrospective-study. Organization:Immune Oncology Rese...,Pediatric Cancer and...,Hematology Center Af..., Search all connections
Abstract Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:ramucirumab,Tiragolumab,Abraxane, Search all connections
Abstract Genomic alterations of cerebrospinal fluid cell-free DNA in leptomeningeal metastases of gastric cancer. Organization:Nanjing Geneseeq Tec...,Geneseeq Research In...,Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort. Organization:Department of Medica...,Department of Oncolo...,Drug:Anlotinib,nivolumab,Target:multi-target tyrosin...,PD-1,Congress:ASCO 2023, Search all connections
Abstract Effect of hypoxic status on survival and therapeutic responses in gastric cancer. Organization:ChosenMed Technology...,Department of Oncolo...,Drug:cell cycle signaling...,Target:cell cycle signaling...,Congress:ASCO 2023, Search all connections
Abstract Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer. Organization:Roswell Park Compreh...,Yokohama City Univer...,Yokohama City Univer...,Drug:CDH1,CDH2,Vimseltinib,Target:CDH2, Search all connections
Abstract Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with esophageal and gastric cancer. Organization:Nanjing Simcere Medi...,Jiangsu simcere diag...,Jiangsu Simcere Diag...,Drug:PARP inhibitors,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Measuring time toxicity of systemic therapies for advanced esophageal and gastric cancers. Organization:Oregon Health & Scie...,Medical Oncology Gro...,Department of Medici...,Drug:pembrolizumab,nivolumab,avelumab, Search all connections
Abstract The identification of blood pattern for gastric cancer from routine blood tests in a territory-wide big clinical database. Organization:Department of Clinic...,The Hong Kong Univer...,Departments of Clini..., Search all connections
Abstract The availability of comprehensive care of gastric cancer in developing countries: Georgian experience. Organization:Todua Clinic,Mardaleishvili Medic...,New Vision Universit...,Congress:ASCO 2023, Search all connections
Abstract A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK. Organization:Institut für Klinisc...,Krankenhaus Nordwest,University Cancer Ce..., Search all connections
Abstract Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response. Organization:Division of Hematolo...,Vanderbilt Universit...,Nashville, TN, Search all connections
Abstract Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial. Clinical trial:DOCET_R_05153,Organization:Asan Medical Center,Chonnam National Uni...,National Cancer Cent..., Search all connections
Abstract Development of an artificial intelligence algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by the Japanese Gastric Cancer Association (JGCA). Organization:National Center for ...,Tokyo, Japan,Healthcare & Life Sc..., Search all connections
Abstract Long-term quality of life and nutritional results of stomach-preserving surgery after sentinel node evaluation in patients with early gastric cancer: A multicenter, randomized phase 3 trial (SENORITA). Organization:National Cancer Cent...,Goyang-Si, South Kor...,Gyeonggi-do, Search all connections
Abstract Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07. Organization:Division of Medical ...,Gifu University, Gif...,Department of Gastro..., Search all connections
Abstract Multi-dimensional cell-free DNA-based liquid biopsy and early detection of gastric cancer. Organization:Department of Gastri...,Congress:ASCO 2023, Search all connections
Abstract Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy. Clinical trial:17-00626,Organization:Division of Hematolo...,Laura and Isaac Perl...,Weill Cornell Medici...,Drug:lenvatinib, Search all connections
Abstract Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Clinical trial:CA209-649,Organization:Princess Margaret Ca...,University Health Ne...,Klinika Onkologii i ..., Search all connections
Abstract Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08). Organization:St. Marianna Univers...,Osaki Citizen Hospit...,Sakai City Medical C..., Search all connections
Abstract Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:Pomalidomide,SOX,S-1, Search all connections
Abstract Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Clinical trial:CA209-649,Organization:Memorial Sloan Kette...,National Cancer Cent...,Johannes-Gutenberg U..., Search all connections
Abstract Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study. Organization:Innovent Biologics, ...,Drug:sintilimab,mFOLFOX6,CAPOX,Target:PD-1,LAG-3, Search all connections
Abstract Beyond scalpels: A meta-analysis of robotic and laparoscopic gastrectomy in long-term oncological outcomes in gastric cancer. Organization:Federal University o...,Universidade Federal...,Congress:ASCO 2024, Search all connections
Abstract LncRNA EGOT and tumorigenesis via Hedgehog pathway in gastric cancer. Organization:Department of Medica...,Department of Medica...,Department of Radiot...,Congress:ASCO 2024, Search all connections
Abstract Immunotherapy-based therapy versus chemotherapy for the neoadjuvant treatment of locally advanced dMMR/MSI-H gastric cancer. Drug:PD-1 inhibitors,CTLA-4,Target:CTLA-4,PD-1,Organization:Laboratory of Gastri...,Congress:ASCO 2024, Search all connections
Abstract Prevalence and outcomes of acute kidney injury among hospitalized patients with gastric cancer: Insights from a National Inpatient Sample study (2018-2020). Organization:Brooklyn Hospital Ce...,Brooklyn Hospital Pr...,The Brooklyn Hospita...,Congress:ASCO 2024,ASCO 2020, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. Drug:Disitamab vedotin,RC48,camrelizumab,Target:PD-1,Organization:Department of Gastro...,Shandong Cancer Hosp...,Shandong First Medic..., Search all connections
Abstract Immuno-based conversion therapy for survival in initially unresectable locally advanced or oligometastatic gastric cancer: A retrospective real-world study with multi-omics analysis. Organization:Shandong University ...,Congress:ASCO 2024, Search all connections
Abstract Exploration of neoadjuvant chemotherapy and post-tumor microenvironment for advanced gastric cancer (GC) or gastroesophageal junction cancer (EGJ). Organization:Chinese People's Lib...,The 5th Medical Cent...,Congress:ASCO 2024, Search all connections
Abstract Immunotherapy plus chemotherapy versus chemotherapy alone in perioperative treatment for locally advanced gastric cancer: A systematic review and meta-analysis. Drug:PD-1 inhibitors,PD-L1 inhibitors,CTX-471,Target:PD-1,PD-L1,Organization:Federal University o...,Federal Univerity of...,Federal University o..., Search all connections
Abstract Life expectancy of patients with early gastric cancer who underwent curative gastrectomy: Comparison with the general population using the Korean Statistical Information Service database. Organization:Asan Medical Center,Seoul National Unive...,South Korea,Congress:ASCO 2024, Search all connections
Abstract Survival outcomes with curative intent hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis. Organization:Loma Linda Universty...,UCSF Fresno,Fresno,Congress:ASCO 2024, Search all connections
Abstract Exploration of different immunogenomic TMEs in gastric cancer based on HER2 and PD-L1 expression. Organization:Samsung Advanced Ins...,Congress:ASCO 2024, Search all connections
Abstract Gastric juice piR-015551: A promising prognostic biomarker for gastric cancer. Organization:Huai 'an Cancer Hosp...,Huai 'an, Jiangsu, C...,Congress:ASCO 2024, Search all connections
Abstract Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment in patients with metastatic gastric cancer (mGC). Drug:venadaparib,Irinotecan,Target:ATM,POLD1,RAD51D, Search all connections
Abstract A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer. Drug:utidelone,sintilimab,oxaliplatin,Target:oxaliplatin,PD-1,tubulin,Organization:Peking University Sh...,Beijing Obstetrics a..., Search all connections
Abstract Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis. Organization:Department of Transl...,Department of Surgic...,Congress:ASCO 2024, Search all connections
Abstract Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study. Drug:serplulimab,platinum-based chemo...,taxanes,Target:Platinum-based chemo...,PD-1,Thymidylate synthase..., Search all connections
Abstract The role of determining HER2neu status in patients with gastric cancer. Organization:CENTEast,Kazakh National Medi...,Kazakhstan Cancer So...,Congress:ASCO 2024, Search all connections
Abstract Analysis of the value of chromosomal instability test for evaluating early efficacy assessment in advanced gastric cancer. Organization:Shanghai Tenth Peopl...,Shanghai Tenth Peopl...,Tongji University Sc...,Congress:ASCO 2024, Search all connections
Abstract Effect of simvastatin on PD-L1 via ILF3 to enhance CD8+ T cell-mediated ferroptosis in gastric cancer cells. Organization:Qilu Hospital of Sha...,Shandong University ...,Congress:ASCO 2024, Search all connections
Abstract Understanding the relationship between obesity and in-hospital outcomes in gastric cancer patients : A nationwide analysis. Organization:State University of ...,Upstate Medical Univ...,Wyckoff Heights Medi...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. Drug:Inetetamab,Trastuzumab,Organization:The Second Affiliate...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospective study. Organization:Ruijin Hospital, Sha...,Ruijin Hospital, Sha...,Congress:ASCO 2024, Search all connections
Abstract Survival outcomes in patients with stage IV gastric cancer with Krukenberg tumors: A systematic review and meta-analysis. Organization:Fatima Jinnah Medica...,Congress:ASCO 2024, Search all connections
Abstract A cross-sectional study of synchronous liver metastasis in patients with gastric cancer. Organization:Zhongda Hospital, So...,Medical School of Un...,Southeast University,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety analysis of first-line tirelizumab combined with paclitaxel-containing chemotherapy regimen in 30 cases of real-world advanced gastric cancer in China. Drug:paclitaxel,tirelizumab,Target:paclitaxel,PD-1,Organization:China-Japan Friendsh...,Beijing University o...,Congress:ASCO 2024, Search all connections
Abstract First-line immunochemotherapy modulates peripheral immune landscape in advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC): Prediction of response to combination therapy. Drug:sintilimab,nivolumab,SOX,Target:PD-1,T cell receptor sign...,NK cell-mediated tox..., Search all connections
Abstract Prevalence of pathogenic genetic variants in patients with gastric cancer ascertained through multi-gene panel testing. Organization:University of Chicag...,Invitae Corporation,The Ohio State Unive...,Congress:ASCO 2024, Search all connections
Abstract GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers. Drug:volrustomig,rilvegostomig,AZD0901,Target:CTLA-4,claudin18.2,PD-1, Search all connections
Abstract A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK. Drug:Atezolizumab,FLOT,Target:VEGFR-1,EGFR-TKI sensitizing...,HER3,Organization:University Cancer Ce...,St. Anna Hospital He..., Search all connections
Abstract 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for detecting occult peritoneal metastasis in locally advanced gastric cancer: A single-center prospective cohort study. Organization:Cancer Center, Shand...,West China Hospital,Sichuan University,Congress:ASCO 2024, Search all connections
Abstract Long-term survival comparison of adjuvant FLOT versus XELOX chemotherapy for locally advanced gastric cancer in a large real-world cohort. Organization:Lanzhou University S...,Lanzhou University S...,Congress:ASCO 2024, Search all connections
Abstract A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001). Drug:BOLD-100,FOLFOX6,Target:ruthenium-based anti...,synergy in establish...,FOLFOX,Organization:Bold Therapeutics In...,Translational Resear..., Search all connections
Abstract Neoadjuvant S-1 plus cisplatin-based chemoradiotherapy compared with surgery alone for locally advanced gastric cancer: Randomized, phase II trial. Drug:S-1,Cisplatin,capecitabine,Target:S-1,thymidylate synthase,oxaliplatin, Search all connections
Abstract Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial. Drug:paclitaxel oral solu...,paclitaxel IV,Target:microtubules,Organization:Ruijin Hospital, Sha...,Congress:ASCO 2024, Search all connections
Abstract Real-world data in Japan for the variants in homologous recombination gene on the etiology of gastric cancer in younger and older patients. Organization:Department of Clinic...,Center for Comprehen...,Center for Comprehen...,Congress:ASCO 2024, Search all connections
Abstract Effect of phosphoproteomic subtyping of gastric cancer on chemotherapy and guidance of targeted cancer therapy. Organization:Institute for Protei...,IMSUT Hospital, The ...,National Institutes ...,Congress:ASCO 2024, Search all connections
Abstract Overall survival results from the phase 2 NIVOFGFR2 study of first-line nivolumab plus CAPOX in patients with FGFR2-positive, PD-L1-positive metastatic gastric cancer. Drug:nivolumab,capecitabine,oxaliplatin,Target:VEGFR2,PD-1,Thymidylate synthase..., Search all connections
Abstract Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649). Drug:nivolumab,chemotherapy,Target:Nivolumab,Programmed cell deat...,Organization:OPEN Health,Clinical trial:CA209-649,Congress:ASCO 2024, Search all connections
Abstract Efficacy of EpCAM CAR-T IMC001 in advanced gastric cancers. Drug:IMC001,Target:EpCAM,Organization:Suzhou Immunofoco Bi...,Congress:ASCO 2024, Search all connections
Abstract Perioperative chemotherapy for patients with gastric cancer with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis. Organization:Department of Biothe...,Congress:ASCO 2024, Search all connections
Abstract A phase 1 study to evaluate the safety and preliminary efficacy of minnelide given alone or in combination with paclitaxel in advanced gastric cancer. Drug:Minnelide,triptolide,paclitaxel,Target:HSP70,beta-tubulin,Organization:Minneamrita Therapeu...,Samsung Medical Cent...,University of Miami ..., Search all connections
Abstract Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. Drug:nivolumab,XELOX,FOLFOXIRI,Target:leucovorin,PD-1,oxaliplatin, Search all connections
Abstract Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2–negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy. Drug:pembrolizumab,oxaliplatin,capecitabine,Target:GCG,PD-1,CXCL9, Search all connections
Abstract Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial. Drug:docetaxel,oxaliplatin,S-1,Target:tubulin,Thymidine kinase 1 (...,dihydrofolate reduct..., Search all connections
Abstract IL33-ST2 axis as a diagnostic and therapeutic biomarker in nivolumab therapy for advanced gastric cancer. Drug:nivolumab,Target:PD-1,Organization:Keio University Hosp...,Congress:ASCO 2024, Search all connections
Abstract Early clues in the battle against advanced gastric cancer: How plasma ctDNA signals the effectiveness of PD-1 inhibitors with chemotherapy. Drug:sintilimab,nivolumab,Target:programmed death 1 (...,Organization:Gastric Cancer Cente...,The First Affiliated...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer: A prospective multicenter phase II study (the TROJAN 021 study). Drug:H101,anti-PD-1 antibodies,Recombinant Human Ad...,Target:PD-1,tumor antigens,tumor cells,Organization:Shanghai Tenth Peopl..., Search all connections
Abstract AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance. Organization:Sammamish, WA,Congress:ASCO 2024, Search all connections
Abstract PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays. Organization:Toho University Grad...,University Clinic of...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies. Organization:Peking University Ca...,The First Affiliated...,Shanghai East Hospit..., Search all connections
Abstract AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individuals Organization:The Hong Kong Univer...,The Chinese Universi...,Department of Clinic..., Search all connections